TRISPECIFIC MOLECULES BINDING BCMA, AND WAYS OF USE THEREOF Russian patent published in 2024 - IPC C07K16/46 C07K19/00 C07K16/28 A61K39/395 C12N15/13 C12N15/62 C12N1/15 C12N1/19 C12N1/21 C12N5/10 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: group of inventions relates to biotechnology. Trispecific binding molecules (TBM) are proposed, which specifically bind to BCMA, a component of human T-cell receptor complex and CD2 or tumour-associated antigen. Antigen-binding module, which specifically binds to human BCMA, contains, according to the Kabat definition, the sequences CDR-L1, CDR-L2 and CDR-L3 presented in SEQ ID NO: 100, 175 and 183, respectively, and sequences CDR-H1, CDR-H2 and CDR-H3 presented in SEQ ID NO: 112, 185 and 122 respectively. Additionally disclosed are conjugates containing TBM, and pharmaceutical compositions containing TBM and conjugates, methods of using TBM for treating diseases and disorders associated with expression of BCMA, a recombinant host cell designed for expression of TBM, and a method of producing TBM by culturing a host cell.

EFFECT: inventions are applicable in cancer therapy, for example, B-cell malignant neoplasms, due to targeting a larger number of malignant B-cells than using bispecific activators, which are aimed only at BCMA and a component of the TCR complex.

31 cl, 5 dwg, 23 tbl, 4 ex